{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:09:55Z","timestamp":1792030195792,"version":"4.4.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.bpobgyn.2008.03.001","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T04:28:09Z","timestamp":1210652889000},"page":"655-676","source":"Crossref","is-referenced-by-count":111,"title":["Medical management of fibroids"],"prefix":"10.1016","volume":"22","author":[{"given":"Srividhya","family":"Sankaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac T.","family":"Manyonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2008.03.001_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.AOG.0000154161.03418.e3","article-title":"Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study","volume":"105","author":"Wise","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1471-0528.2006.00885.x","article-title":"Long-term follow-up of uterine artery embolisation \u2013 an effective alternative in the treatment of fibroids","volume":"113","author":"Walker","year":"2006","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/humrep\/12.9.1927","article-title":"Laparoscopic myomectomy: indications, surgical technique and complications","volume":"12","author":"Seinera","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0015-0282(99)00061-8","article-title":"The excision of uterine fibroids by vaginal myomectomy: a prospective study","volume":"71","author":"Davies","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajog.2004.03.037","article-title":"Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multi-centre study","volume":"191","author":"Spies","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2214\/ajr.183.6.01831713","article-title":"MRI guidance of focused ultrasound therapy of uterine fibroids: early results","volume":"183","author":"Hindley","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1471-0528.2004.00414.x","article-title":"Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies","volume":"112","author":"Carpenter","year":"2005","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib8","unstructured":"United States of America Food And Drug Administration. Center For Devices And Radiological Health Medical Devices Advisory Committee. Obstetrics And Gynecology Devices Panel, 68th Meeting, June 3, 2004. Available from: <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/transcripts\/2004-4046tl.htm>"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib9","series-title":"Guide to the methods of technology appraisal","author":"National Institute for Clinical Excellence","year":"2004"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib10","first-page":"20","article-title":"Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue","volume":"55","author":"Wilson","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00016348509155136","article-title":"Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium","volume":"64","author":"Tamaya","year":"1985","journal-title":"Acta Obstet Gynaecol Scand"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib12","first-page":"53","article-title":"The neuroendocrine control of the menstrual cycle","volume":"36","author":"Knobil","year":"1980","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0600305","article-title":"Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmunoassay","volume":"60","author":"Jeffcoate","year":"1974","journal-title":"J Endocrinol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","article-title":"Clinical pharmacokinetics of depot leuprorelin","volume":"41","author":"Periti","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0412.2003.00049.x","article-title":"Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure","volume":"82","author":"Bozzini","year":"2003","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1071-5576(02)00184-3","article-title":"Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma","volume":"10","author":"Chegini","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/molehr\/8.12.1071","article-title":"Effects of GnRH analogues, \u2018add-back\u2019 steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression","volume":"12","author":"Chegini","year":"2002","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1071-5576(03)00004-2","article-title":"Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy","volume":"10","author":"Chegini","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0015-0282(97)81394-5","article-title":"Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata","volume":"67","author":"Deligdisch","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0002-9378(94)70332-9","article-title":"The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study","volume":"170","author":"Reinsch","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib21","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0002-9378(97)70397-1","article-title":"Immunohistochemistry of vascular changes in leuprolide acetate-treated leiomyomas","volume":"176","author":"Mesia","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0029-7844(95)00191-S","article-title":"Leuprolide acetate treatment and myoma arterial size","volume":"86","author":"Rutgers","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0015-0282(16)61022-1","article-title":"A randomized, placebo controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy","volume":"52","author":"Friedman","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib24","first-page":"720","article-title":"Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study","volume":"77","author":"Friedman","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib25","first-page":"856","article-title":"A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata","volume":"74","author":"Schlaff","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib26","first-page":"481","article-title":"Clinical use of naferelin in the treatment of leiomyomas. A review of the literature","volume":"45","author":"Minaguchi","year":"2000","journal-title":"J Reprod Med"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0015-0282(03)00261-9","article-title":"A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy","volume":"79","author":"Donnez","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib28","first-page":"104","article-title":"The prevention of bone loss in young women treated with GnRH analogues with \u2018add-back\u2019 estrogen therapy","volume":"81","author":"Leather","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0015-0282(16)59288-7","article-title":"Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot","volume":"48","author":"West","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0015-0282(16)57729-2","article-title":"Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri","volume":"64","author":"Scialli","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0015-0282(98)00128-9","article-title":"A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata","volume":"70","author":"Palomba","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib32","first-page":"222","article-title":"The effect of add-back treatment with tibolone on patients with myoma uteri treated with triptorelin","volume":"29","author":"Gocmen","year":"2002","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.pgp.0000163848.29506.67","article-title":"Expression of proliferating cell nuclear antigen and Bcl-2 during a pseudomenopausal state induced by presurgical treatment of uterine leiomyomas with gonadotropin-releasing hormone analogues plus tibolone","volume":"24","author":"de Falco","year":"2005","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0015-0282(99)00366-0","article-title":"Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles","volume":"72","author":"Palomba","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib35","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/humrep\/17.12.3213","article-title":"Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial","volume":"17","author":"Palomba","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib36","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1210\/jc.2002-020780","article-title":"Raloxifene administration in women treated with gonadotropin releasing agonist for uterine leiomyomas: effects on bone metabolism","volume":"87","author":"Palomba","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.fertnstert.2003.11.061","article-title":"Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood and quality of life","volume":"82","author":"Palomba","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib38","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/humrep\/deh296","article-title":"Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas","volume":"19","author":"Palomba","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/oxfordjournals.humrep.a137643","article-title":"Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids","volume":"7","author":"West","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/humrep\/12.3.436","article-title":"Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability","volume":"12","author":"Caird","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1210\/jc.76.5.1217","article-title":"An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective randomized double blind placebo-controlled crossover trial","volume":"76","author":"Carr","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0015-0282(16)59763-5","article-title":"A randomized double-blind trial of a gonadotropin releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri","volume":"49","author":"Friedman","year":"1988","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09513599909167584","article-title":"Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata","volume":"13","author":"Nakayama","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1210\/jc.76.6.1439","article-title":"A prospective, randomized trial of gonadotropin releasing hormone agonist plus estrogen-progestin or progestin \u2018add-back\u2019 regimens for women with leiomyomata uteri","volume":"76","author":"Friedman","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib45","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/oxfordjournals.humrep.a138762","article-title":"Longterm medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin \u2018add-back\u2019 for 2 years","volume":"9","author":"Friedman","year":"1994","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000249","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","volume":"2","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/humrep\/13.4.873","article-title":"Abdominal myomectomy for infertility: a comprehensive review","volume":"13","author":"Vercellini","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib48","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/humrep\/16.8.1726","article-title":"Laparoscopic myomectomy: predicting the risk of conversion to an open procedure","volume":"16","author":"Dubuisson","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib49","first-page":"285","article-title":"Surgical alternatives to hysterectomy in the management of leiomyomas","volume":"73","author":"ACOG Practice Bulletin","year":"2001","journal-title":"Int\u00a0J\u00a0Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/humrep\/14.1.44","article-title":"Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues","volume":"14","author":"Campo","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1471-0528.2003.02107.x","article-title":"Laparoscopic myomectomy for fibroids penetrating the uterine cavity: is it a safe procedure?","volume":"110","author":"Seracchioli","year":"2003","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib52","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1471-0528.2002.01224.x","article-title":"Cost-effectiveness of preoperative gonadotrophin releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy","volume":"109","author":"Farquhar","year":"2002","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijgo.2007.05.050","article-title":"A systematic review of randomized controlled trials to reduce hemorrhage during myomectomy for uterine fibroids","volume":"100","author":"Kongnyuy","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib54","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0015-0282(03)00362-5","article-title":"Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial","volume":"79","author":"Vercellini","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib55","series-title":"LHRH and its analogs","first-page":"95","article-title":"Comparison of LHRH agonists and antagonists antifertility and therapeutic developments","author":"Corbin","year":"1984"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib56","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0015-0282(16)54018-7","article-title":"Novel regimen of gonadotropin releasing (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction","volume":"54","author":"Gordon","year":"1990","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib57","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/humrep\/13.11.3023","volume":"13","author":"The Ganerelix Dose Finding Study Group","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543784.14.9.1085","article-title":"New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists","volume":"14","author":"Schultze-Mosgau","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0015-0282(16)56214-1","article-title":"Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist","volume":"60","author":"Kettel","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib60","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/humrep\/12.9.2028","article-title":"Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix","volume":"12","author":"Gonzalez-Barcena","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib61","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1471-0528.2004.00504.x","article-title":"Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix","volume":"112","author":"Flierman","year":"2005","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000185507","article-title":"In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators","volume":"48","author":"Mitlak","year":"1997","journal-title":"Horm Res"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib63","first-page":"431","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib64","first-page":"1131","article-title":"Raloxifene: a selective estrogen receptor modulator","volume":"60","author":"Janine","year":"1990","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(01)01849-0","article-title":"Effect of raloxifene treatment on uterine leiomyomas in postmenopausal women","volume":"76","author":"Palomba","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib66","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/jc.87.8.3603","article-title":"Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study","volume":"87","author":"Palomba","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ogc.2005.12.001","article-title":"Steroid hormones and leiomyomas","volume":"33","author":"Marsh","year":"2006","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.fertnstert.2003.06.009","article-title":"Raloxifene prevents the growth of uterine leiomyomas in premenopausal women","volume":"81","author":"Jirecek","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib69","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettingrr","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005287.pub3","article-title":"Selective estrogen receptor modulators (SERMs) for uterine leiomyomas","volume":"4","author":"Wu","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib71","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-2004-823027","article-title":"Aromatase and leiomyoma of the uterus","volume":"22","author":"Shozu","year":"2004","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib73","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/gme.0b013e318054e2be","article-title":"Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata","volume":"14","author":"Kaunitz","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib74","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0015-0282(02)04761-1","article-title":"Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor","volume":"79","author":"Shozu","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib75","series-title":"Evidence-based clinical guideline No. 5","author":"The management of menorrhagia in secondary care","year":"1999"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004347-198609000-00005","article-title":"Endometrial morphology during long term use of levonorgestrel releasing intra-uterine devices","volume":"5","author":"Silverberg","year":"1986","journal-title":"Int J Gynaecol Pathol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","article-title":"Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatmentof idiopathic menorrhagia","volume":"105","author":"Irvine","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib78","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/bmj.316.7138.1122","article-title":"Open randomised study of use of levonorgestrel releasing intrauterine system as an alternative to hysterectomy","volume":"316","author":"Lahteenmaki","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib79","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(00)03615-1","article-title":"Quality of life and cost effectiveness of levonorgestrel releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial","volume":"35","author":"Hurskainen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib80","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.291.12.1456","article-title":"Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. Randomised trial 5-year follow up","volume":"291","author":"Hurskainen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib81","article-title":"Progesterone\/progestagen releasing intrauterine system versus either placebo or any other medication for heavy menstrual bleeding","volume":"2","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib82","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/humrep\/16.10.2103","article-title":"Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium","volume":"16","author":"Maruo","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib83","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.contraception.2007.01.025","article-title":"Effects of levonorgestrel-releasing IUS ands progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas","volume":"75","author":"Maruo","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib84","series-title":"Heavy menstrual bleeding: clinical guideline","author":"National Collaborating Centre for Women's and Children's Health","year":"2007"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","article-title":"Effects of progesterone on uterine leiomyoma growth and apoptosis","volume":"65","author":"Manzo","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib86","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/00002018-200225110-00002","article-title":"A benefit-risk assessment of medical treatment for uterine leiomyomas","volume":"25","author":"De Leo","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0029-7844(02)02511-5","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib88","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib89","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ogc.2005.12.011","article-title":"Future directions in myoma research","volume":"33","author":"Brahma","year":"2006","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib90","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/humrep\/deh738","article-title":"The effects of 1-month administration of asoprisnil (J867),\u00a0a selective progesterone receptor modulator, in healthy premenopausal women","volume":"20","author":"Chwalisz","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib91","first-page":"636","article-title":"Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM)","volume":"10","author":"Chwalisz","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib92","first-page":"728","article-title":"Effects of the novel selective progesterone receptor modulator (SPRM) asoprisinil on bleeding patterns in subjects with leiomyomata","volume":"11","author":"Chwalisz","year":"2004","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib93","first-page":"445","article-title":"Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression","volume":"28","author":"Melli","year":"2007","journal-title":"Saudi Med J"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib94","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0015-0282(03)00070-0","article-title":"Hemodynamic effect of danazol therapy in women with uterine leiomyomata","volume":"79","author":"La Marca","year":"2003","journal-title":"Fertil Steril"},{"issue":"Suppl 12","key":"10.1016\/j.bpobgyn.2008.03.001_bib95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1471-0528.1995.tb09159.x","article-title":"Histological impact of medical therapy \u2013 clinical implications","volume":"102","author":"Fedele","year":"1995","journal-title":"Br\u00a0J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib96","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000010118","article-title":"Short-term treatment of uterine fibromyomas with danazol","volume":"47","author":"De Leo","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib97","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/humrep\/12.2.357","article-title":"Danazol administration after gonadotrophin-releasing hormone analogue reduces rebound of uterine myomas","volume":"12","author":"De Leo","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09513598709082692","article-title":"Placebo-controlled comparison of danazol and medroxyprogesterone acetate in the treatment of endometriosis","volume":"1","author":"Telimaa","year":"1987","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib99","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.fertnstert.2004.08.004","article-title":"Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply","volume":"82","author":"La Marca","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/aogs.1989.68.s150.39","article-title":"Gestrinone in the treatment of myomas","volume":"150","author":"Coutinho","year":"1989","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000293212","article-title":"Treatment of large fibroids with high doses of gestrinone","volume":"30","author":"Coutinho","year":"1990","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib102","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0015-0282(16)60722-7","article-title":"Long-term treatment of leiomyomas with gestrinone","volume":"51","author":"Coutinho","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2004-828618","article-title":"Potential nonhormonal therapeutics for medical treatment of leiomyomas","volume":"22","author":"Young","year":"2004","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0897.1998.tb00383.x","article-title":"Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells","volume":"40","author":"Lee","year":"1998","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib105","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0002-9440(10)64323-4","article-title":"Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells","volume":"162","author":"Mason","year":"2003","journal-title":"Am J Pathol"},{"issue":"Suppl 5","key":"10.1016\/j.bpobgyn.2008.03.001_bib106","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1289\/ehp.00108s5849","article-title":"Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors","volume":"108","author":"Nowak","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.bpobgyn.2008.03.001_bib107","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/molehr\/gah199","article-title":"Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone","volume":"11","author":"Loy","year":"2005","journal-title":"Mol Hum Reprod"},{"issue":"1","key":"10.1016\/j.bpobgyn.2008.03.001_bib108","article-title":"A clinician's guide to the use of gonadotropin-releasing hormone analogues in women","volume":"2","author":"Moghissi","year":"2000","journal-title":"MedGenMed"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693408000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693408000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T05:19:59Z","timestamp":1557551999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693408000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S1521693408000461"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2008.03.001","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}